Table I.

Clinicopathological features and CD103⁺ cell count of the patients with renal cell carcinoma included in the present study.

A, Training group (n=100)
	CD103+ cell count
Parameter	Low, n (%)	High, n (%)	P-value
Age, years
<61	26 (38.2)	42 (61.8)	0.161
≥61	17 (53.1)	15 (46.9)
Gender
Male	14 (36.8)	24 (63.2)	0.330
Female	29 (46.8)	33 (53.2)
Grade
I+II	17 (41.5)	24 (58.5)	0.796
III+IV	26 (44.1)	33 (55.9)
T stage
T1+T2	16 (50.0)	16 (50.0)	0.332
T3+T4	27 (39.7)	41 (60.3)
Lymph node
N0-N2	17 (37.0)	29 (63.0)	0.260
N3-N4	26 (48.1)	28 (51.9)
Metastasis
Negative	36 (41.9)	50 (58.1)	0.568
Positive	7 (50.0)	7 (50.0)
TNM stage
I+II	13 (28.9)	32 (71.1)	0.010
III+IV	30 (54.5)	25 (45.5)
Patient status
Alive	5 (13.5)	32 (86.5)	P<0.001
Succumbed	38 (60.3)	25 (39.7)
B, Testing group (n=100)
	CD103+ cell count
Parameter	Low, n (%)	High, n (%)	P-value
Age, years
<62	28 (43.7)	36 (56.3)	0.148
≥62	12 (33.3)	24 (66.7)
Sex
Male	19 (41.3)	27 (58.7)	0.307
Female	21 (39.6)	32 (60.4)
Grade
I+II	15 (33.3)	30 (66.7)	0.218
III+IV	25 (45.5)	30 (54.5)
T stage
T1+T2	22 (47.8)	24 (52.2)	0.140
T3+T4	18 (33.3)	36 (66.7)
Lymph node
N0-N2	20 (37.7)	33 (62.3)	0.624
N3-N4	20 (42.6)	27 (57.4)
Metastasis
Negative	32 (38.6)	51 (61.4)	0.514
Positive	8 (47.1)	7 (52.9)
TNM stage
I+II	15 (30.0)	35 (70.0)	0.041
III+IV	25 (50.0)	25 (50.0)
Patient status
Alive	13 (25.0)	39 (75.0)	0.001
Succumbed	27 (56.2)	21 (43.8)

TNM, tumor-node-metastasis; CD, cluster of differentiation.